The opening price on the SWX was CHF 113, 15.3% higher. This corresponds to a market capitalisation of CHF 834 mio.
According to the listing prospectus, of the 7,380,141 registered shares entered in the Commercial Register 2,100,000 or 28.5% of all outstanding shares were placed with the public. If the option for more shares (over-allotment option) is chosen, this proportion may rise to 31.4%. The 2'100'000 of the placed shares proceed from a capital increase connected with the IPO.
Basilea Pharmaceutica Ltd, founded in 2000, is an independent biopharmaceutical company headquartered in Basel, Switzerland that is engaged in the discovery and development of innovative medicines for the treatment of unmet medical needs. The company's fully integrated research and development operations
